Liraglutide for weight loss: what TikTok gets wrong

What did @therecenterwellness actually say?

The creator described liraglutide as a GLP-1 receptor agonist similar to semaglutide, with the key difference being that it requires a daily injection rather than a weekly one. They made a specific behavioral claim: that the daily dosing "is giving people more accountable." They also said food noise and hunger are "much more managed" because of the daily injection schedule, and listed side effects including nausea, acid reflux, constipation, and fatigue. The video ends with a vague forward-looking statement that liraglutide "will likely be as much more in the future" — which is grammatically unclear but seems to predict the drug's growth in popularity.

Worth noting: the creator consistently mispronounces the drug as "lyroglutide" throughout the video. That is a minor issue but matters for a 43,000-view health video where viewers might search for the wrong drug name.

Does the science back this up?

The basic pharmacology claim is accurate. The accountability and hunger-management claims tied specifically to daily dosing are not well supported by the clinical literature, and that is a meaningful distinction.

Liraglutide (brand name Saxenda for weight loss, Victoza for type 2 diabetes) does require once-daily subcutaneous injection, while semaglutide (Ozempic, Wegovy) is administered weekly. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) established liraglutide 3.0 mg as effective for weight loss, with participants losing an average of 8.4 kg versus 2.8 kg for placebo over 56 weeks. That is real and meaningful efficacy.

However, the claim that daily dosing specifically drives better accountability or hunger management compared to weekly dosing is not supported by head-to-head trial data the creator cited, because they cited none. The STEP 8 trial (Rubino et al., 2022, JAMA) directly compared semaglutide 2.4 mg weekly to liraglutide 3.0 mg daily and found semaglutide produced significantly greater weight loss. Hunger suppression data from that trial did not favor liraglutide's daily schedule.

What did they get wrong (or right)?

They got the drug class right, the dosing frequency right, and the side effect profile largely right. That is real credit. But the accountability and hunger-management framing is where things go sideways.

The idea that injecting yourself every day makes you more accountable is a behavioral hypothesis, not an established clinical finding. It has some intuitive logic, but intuition is not data. The creator presents it as observed clinical fact: "we are seeing that this is giving people more accountable." That phrasing implies practice-level evidence, which is anecdotal at best. No peer-reviewed literature supports daily GLP-1 dosing as producing superior accountability outcomes compared to weekly dosing.

The side effect list is reasonable but incomplete. The creator omitted some clinically important ones from the liraglutide label, including increased heart rate, which the FDA requires to be monitored, and the boxed warning about thyroid C-cell tumors seen in rodent studies. To be fair, that warning applies to the broader GLP-1 class, but a 44,000-view video on a specific drug probably should not skip the black box.

• Correct: Daily vs. weekly dosing distinction
• Correct: GLP-1 class comparison to semaglutide
• Correct: Core side effect profile
• Incorrect: Accountability and hunger benefits tied to daily dosing frequency
• Omitted: FDA boxed warning on thyroid C-cell tumors
• Omitted: Increased resting heart rate as a known side effect

What should you actually know?

Liraglutide is a legitimate, FDA-approved GLP-1 medication with a strong clinical track record, but if your goal is weight loss and you are comparing it to semaglutide, the evidence favors semaglutide. That is not a subtle difference.

In the STEP 8 trial (Rubino et al., 2022, JAMA), participants on semaglutide 2.4 mg lost 15.8% of body weight compared to 6.4% for liraglutide 3.0 mg over 68 weeks. That is more than double the weight loss. If a prescriber is choosing between them for weight management specifically, the data should drive that conversation, not a theory about daily injections building better habits.

Liraglutide does still have appropriate use cases. Some patients do better with daily routines. Some may have tolerability profiles that favor liraglutide over semaglutide. The drug has a longer post-market safety record. These are legitimate clinical considerations. But the framing in this video, that daily dosing is a feature rather than just a logistical difference, reverses what the comparative data actually shows.

If you are considering liraglutide or any GLP-1 medication, talk to a licensed provider who can review your full medical history, including any personal or family history of thyroid cancer, which represents a contraindication for this drug class.